Status:

COMPLETED

Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma

Lead Sponsor:

Weill Medical College of Cornell University

Collaborating Sponsors:

Bayer

Conditions:

T-Cell Lymphoma

Lymphoma, Non-Hodgkin's

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

Primary Objective: * To determine the toxicity profile and tolerability of alemtuzumab (Campath) when administered in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP...

Eligibility Criteria

Inclusion

  • Patients must have a diagnosis of non-B-cell, non-Hodgkin's lymphoma (including T-cell, null-cell, or NK-cell lymphoma, but excluding lymphoblastic lymphoma)
  • Stage II, III, or IV disease requiring chemotherapy
  • At least one site of measurable disease, 1.5 cm in diameter or greater
  • Age \> or = 18 years
  • Absolute granulocyte count of at least 1500 cells/mm3, unless neutropenia is due to marrow infiltration by the tumor
  • Platelet count of at least 100,000 cells/mm3 unless thrombocytopenia is due to marrow infiltration by tumor
  • Creatinine less than 2 x upper limits of normal (ULN)
  • Total bilirubin less than 2 x ULN (dose reduced vincristine and adriamycin required for bilirubin \> 1.2 mg/dL)
  • Echocardiogram (Echo) or multiple gate acquisition scan (MUGA) documenting a normal ejection fraction prior to chemotherapy
  • Able to give informed consent

Exclusion

  • Known central nervous system (CNS) involvement
  • Known HIV disease
  • Patients who are pregnant or nursing
  • Any factor which might limit the patient's ability to provide informed consent
  • Life expectancy \< 3 months
  • Patients who are unwilling to agree to use an effective means of birth control while on treatment

Key Trial Info

Start Date :

July 1 2004

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00161590

Start Date

July 1 2004

Last Update

October 22 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Weill Medical College of Cornell University

New York, New York, United States, 10021

Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma | DecenTrialz